(Part one of a four-part series)

Results from COMPASS Pathways (NASDAQ: CMPS)’ Phase 2b trial assessing the safety of different doses of proprietary synthetic psilocybin paired with psychotherapy for Treatment-Resistant Depression (TRD) were recently published in the New England Journal of Medicine. 

The study took place at 22 sites in the US, Canada, the UK and seven European countries and enrolled 233 participants who had TRD, meaning they had not responded to two prior courses of antidepressants.

Noting data that approximately 100 million people globally have TRD and, of the nine million in the U.S. with medically treated depression, an estimated one-third of them, or three million, are resistant to treatment. As the publication explains, people with this condition are at a high risk of physical illness, disability, hospitalization and suicide. 

Double-blind and randomized, the trial divided participants into …

Full story available on Benzinga.com